DK0415522T3 - Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat - Google Patents

Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat

Info

Publication number
DK0415522T3
DK0415522T3 DK90307044.9T DK90307044T DK0415522T3 DK 0415522 T3 DK0415522 T3 DK 0415522T3 DK 90307044 T DK90307044 T DK 90307044T DK 0415522 T3 DK0415522 T3 DK 0415522T3
Authority
DK
Denmark
Prior art keywords
reducing
hydrochloride dihydrate
ondansetron hydrochloride
crystal size
size
Prior art date
Application number
DK90307044.9T
Other languages
Danish (da)
English (en)
Inventor
David Trevor Collin
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=10659180&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0415522(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Application granted granted Critical
Publication of DK0415522T3 publication Critical patent/DK0415522T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D249/00Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/081,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Glass Compositions (AREA)
  • Iron Core Of Rotating Electric Machines (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
DK90307044.9T 1989-06-28 1990-06-27 Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat DK0415522T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB898914804A GB8914804D0 (en) 1989-06-28 1989-06-28 Process

Publications (1)

Publication Number Publication Date
DK0415522T3 true DK0415522T3 (da) 1994-09-19

Family

ID=10659180

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90307044.9T DK0415522T3 (da) 1989-06-28 1990-06-27 Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat

Country Status (20)

Country Link
US (1) US5622720A (fr)
EP (1) EP0415522B1 (fr)
JP (1) JP3093242B2 (fr)
KR (1) KR0182789B1 (fr)
AT (1) ATE110380T1 (fr)
AU (1) AU637110B2 (fr)
CA (1) CA2019944C (fr)
DE (1) DE69011786T2 (fr)
DK (1) DK0415522T3 (fr)
ES (1) ES2060045T3 (fr)
GB (1) GB8914804D0 (fr)
HK (1) HK44495A (fr)
HU (1) HU208009B (fr)
IE (1) IE64715B1 (fr)
IL (1) IL94888A (fr)
NZ (1) NZ234267A (fr)
RU (1) RU2002745C1 (fr)
SA (1) SA90110025B1 (fr)
UA (1) UA18249A (fr)
ZA (1) ZA905002B (fr)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9310756D0 (en) * 1993-05-25 1993-07-14 Glaxo Lab Sa Compositions
GB9423511D0 (en) * 1994-11-22 1995-01-11 Glaxo Wellcome Inc Compositions
RU2162695C1 (ru) * 2000-07-14 2001-02-10 ООО с иностранными инвестициями "Редди-Биомед лимитед" Способ получения ондансетрона гидрохлорида дигидрата, субстанция и фармацевтический препарат
US20020115707A1 (en) * 2001-01-11 2002-08-22 Rami Lidor-Hadas Process for preparing pure ondansetron hydrochloride dihydrate
RU2185825C1 (ru) * 2001-03-12 2002-07-27 Государственный научный центр - Институт биофизики Фармацевтическая композиция, содержащая ондансетрон и метацин
HRP20040767A2 (en) * 2002-02-19 2004-12-31 Teva Pharma Desolvating solvates of atorvastatin hemi-calcium
WO2003082804A1 (fr) 2002-03-28 2003-10-09 Synthon B.V. Besylate de venlafaxine
DK1499623T3 (da) 2002-04-29 2007-10-08 Teva Gyogyszerg Ar Zartkoeruee Fremgangsmåde til fremstilling af 1,2,3,9-tetrahydro-9-methyl-3-[(2-methyl-1H-imidazol-1-yl)methyl]-4H-carbazol-4-on
US20050131045A1 (en) * 2002-04-30 2005-06-16 Judith Aronhime Novel crystal forms of ondansetron, processes for their preparation, pharmaceutical, compositions containing the novel forms and methods for treating nausea using them
US20060083759A1 (en) * 2002-07-17 2006-04-20 Aleksander Resman Stabilization of the profile of release of active substances from a formulation
DE10393729T5 (de) * 2002-11-15 2005-10-13 Helsinn Healthcare S.A. Verfahren zur Behandlung von Emesis
US8598219B2 (en) 2003-01-30 2013-12-03 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
JO2735B1 (en) * 2003-01-30 2013-09-15 هيلسين هيلث كير أس ايه. Liquid pharmaceutical formulations of palonosetron
MY143789A (en) * 2003-02-18 2011-07-15 Helsinn Healthcare Sa Use of palonosetron treating post- operative nausea and vomiting
US7390503B1 (en) 2003-08-22 2008-06-24 Barr Laboratories, Inc. Ondansetron orally disintegrating tablets
US20060167072A1 (en) * 2004-01-30 2006-07-27 Helsinn Healthcare Sa Liquid pharmaceutical formulations of palonosetron
US7288660B2 (en) 2004-05-07 2007-10-30 Taro Pharmaceutical Industries Limited Process for preparing ondansetron hydrochloride dihydrate having a defined particle size
UA88186C2 (ru) * 2005-02-23 2009-09-25 Тева Фармасьютикл Индастриз, Лтд. Расагилиновые формуляции с улучшенной однородностью содержимого
CA2901244A1 (fr) * 2005-02-23 2006-08-31 Teva Pharmaceutical Industries, Ltd. Preparations de rasagiline presentant une uniformite de teneur amelioree
CA2646250A1 (fr) 2006-04-03 2007-10-18 Teva Pharmaceutical Industries Ltd. Utilisation de rasagiline pour le traitement du syndrome des jambes sans repos
KR101441459B1 (ko) * 2006-10-24 2014-09-18 헬신 헬쓰케어 에스.에이. 안정성 및 생체이용률이 개선된 염산 팔로노세트론을 포함하는 연질 캡슐

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE460359B (sv) * 1984-01-25 1989-10-02 Glaxo Group Ltd 3-imidazolylmetyltetrahydrokarbazoloner, foerfarande foer framstaellning av dessa och en farmaceutisk komposition
US4695578A (en) * 1984-01-25 1987-09-22 Glaxo Group Limited 1,2,3,9-tetrahydro-3-imidazol-1-ylmethyl-4H-carbazol-4-ones, composition containing them, and method of using them to treat neuronal 5HT function disturbances
JP2608078B2 (ja) * 1986-12-17 1997-05-07 グラクソ、グループ、リミテッド 医 薬
DK185489A (da) * 1988-04-22 1989-10-23 Duphar Int Res Imidazolylmethyl-cycloalkanoebaaindoloner, deres fremstilling og anvendelse
US5344658A (en) * 1989-06-28 1994-09-06 Glaxo Group Limited Process and composition using ondansetron

Also Published As

Publication number Publication date
HU208009B (en) 1993-07-28
EP0415522B1 (fr) 1994-08-24
CA2019944A1 (fr) 1990-12-28
IL94888A (en) 1995-03-15
JPH0395178A (ja) 1991-04-19
US5622720A (en) 1997-04-22
JP3093242B2 (ja) 2000-10-03
DE69011786D1 (de) 1994-09-29
HK44495A (en) 1995-03-31
RU2002745C1 (ru) 1993-11-15
NZ234267A (en) 1992-11-25
IE64715B1 (en) 1995-08-23
KR0182789B1 (ko) 1999-10-15
ES2060045T3 (es) 1994-11-16
AU637110B2 (en) 1993-05-20
GB8914804D0 (en) 1989-08-16
SA90110025B1 (ar) 2001-03-24
HUT54140A (en) 1991-01-28
CA2019944C (fr) 2000-05-09
ATE110380T1 (de) 1994-09-15
HU904015D0 (en) 1990-12-28
IL94888A0 (en) 1991-04-15
ZA905002B (en) 1991-12-24
IE902333L (en) 1990-12-28
EP0415522A1 (fr) 1991-03-06
IE902333A1 (en) 1991-01-16
AU5787490A (en) 1991-01-03
KR910000709A (ko) 1991-01-30
DE69011786T2 (de) 1994-12-15
UA18249A (uk) 1997-12-25

Similar Documents

Publication Publication Date Title
DK0415522T3 (da) Fremgangsmåde til reducering af krystalstørrelsen af ondansetron-hydrochlorid-dihydrat
FR2669635B1 (fr) Procede de fabrication d'hydroxymethylfurfural (hmf) du purete elevee.
PT73259A (en) Process for preparing novel substituted pyrazinyl-1,2,4-oxadiazole-5-ones
ES2023509B3 (es) Producto granular (i).
DE68917003D1 (de) Verfahren zur Herstellung von Halbleiterbauelementen, die gegen Musterverunreinigungen geschützt sind.
ZA922504B (en) Novel 2-spirocyclopropyl 4-acylcephems and processes for the preparation thereof
DK0508191T3 (da) Fremgangsmåde til fremstilling af 1-carbamoyl-pyrazoler
NO905012D0 (no) Fremgangsmaate til fremstilling av cefemer, oksacefemer ogkarbacefemer og 3-sulfonyloksy-substituerte cefemer, oksacefemer og karbacefemer som utgangsprodukt ved fremgangsmaaten.
JPS51126841A (en) Reinforced light-fiber
JPS525700A (en) The process for production of silicon nitride
JPS52137944A (en) Time supervisory system of input output non-synchronous singnal
JPS53145517A (en) Video amplifier circuit
DE69004244D1 (de) Verfahren zur Herstellung von hohen Anteilen des trans,trans-Isomeren enthaltenden 4,4'-Diisocyanatodicyclohexylmethan.
JPS51122095A (en) A process for preparing imidazobenzenediazepine derivatives
JPS53100562A (en) Apparatus for separating aligning disk-shaped articles
JPS51123064A (en) Forming process of bonding-pad area
JPS5225388A (en) Apparatus for changing the direction of goods being conveyed
JPS5277593A (en) Temperature compensating circuit of semiconductor strain meter
JPS522961A (en) Articles transfer conveyor
JPS5293787A (en) Novel process for preparation of cephem derivatives
JPS51120302A (en) Process for controlling turbine
DE3576498D1 (de) 2-sulfamoyl-1h-indole-derivate zur behandlung von hohem intraocularem druck.
MY8600520A (en) N-aryl-n (1,4,5,6-tetrahydropyrimidin-2-yl) or (4,5,6,7-tetrahydro-1-h-1,3-diazepin-2-yl) ureas for intestinal disorders and as antihypertensives
JPS53147186A (en) On off controller
JPS51125219A (en) Process for preparation of 2- (silylamino)alkanenitrile